The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of oral melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM).
T. Kazamel
No relevant relationships to disclose
J. R. Berenson
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
O. Yellin
No relevant relationships to disclose
R. V. Boccia
No relevant relationships to disclose
J. Matous
No relevant relationships to disclose
K. A. Dressler
No relevant relationships to disclose
Y. Nassir
No relevant relationships to disclose
S. Rothstein
Employment or Leadership Position - Novartis
R. Swift
Honoraria - Novartis